SIGNIFOR LAR Rx
Generic Name and Formulations:
Pasireotide pamoate 20mg, 40mg, 60mg; pwd for IM inj after reconstitution.
Novartis Pharmaceuticals Corp
Indications for SIGNIFOR LAR:
Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.
Give by IM inj into the right or left gluteus. Initially 40mg every 4 weeks (28 days); may increase dose to max 60mg after 3 months if GH and/or IGF-1 levels not normalized. If over-response to treatment, may decrease in 20mg decrements. Hepatic impairment: moderate (Child-Pugh B): initially 20mg every 4 weeks; max: 40mg every 4 weeks; severe (Child-Pugh C): avoid.
<18yrs: not established.
Monitor for adrenal insufficiency; give steroid replacement therapy if confirmed. Risk of hyperglycemia; initiate or adjust antidiabetic treatment if occurs; reduce dose or discontinue if remains uncontrolled. Monitor HbA1c and FPG prior to initiation, weekly for first 3 months, 4–6 weeks after dose increase, and thereafter as indicated. Congenital long QT prolongation. Cardiac disease (eg, recent MI, CHF, unstable angina, significant bradycardia); monitor QT interval at 21 days. High-grade heart block. Hypokalemia and/or hypomagnesemia; correct and monitor electrolytes prior to starting and during therapy. Monitor liver tests prior to initiation, 2–3 weeks after, then monthly for 3 months, then as indicated. Discontinue if significant hepatic impairment develops. Monitor baseline ECG, pituitary function prior to initiation and periodically during treatment. Renal impairment: not studied. Premenopausal women: potential for unintended pregnancy due to improved fertility. Pregnancy. Nursing mothers.
Cyclohexapeptide somatostatin analog.
Caution with antiarrhythmics or other drugs that may prolong the QT interval. May antagonize cyclosporine (adjust dose). May potentiate bromocriptine; dose reduction may be needed.
Diarrhea, hyperglycemia, diabetes, cholelithiasis (monitor); bradycardia, QT prolongation, pituitary hormone deficiency.
Single-use kit—1 (w. diluents, supplies)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Panel Recommends Earlier Body Weight Monitoring in Use of Mood Stabilizers
- Nondaily Cigarette Use Increasing Among Individuals With Mental Health, Substance Use Disorders
- Cesarean Delivery, Early Childhood Antibiotic Use Not Associated With Risk for ADHD
- Uncertainty as a Form of Violence: Current Immigration Policy and Crisis
- FDA Gets Tough on Juul, Other Electronic Cigarette Makers